Tigermed Consulting Co., Ltd   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Hangzhou China (2004)

Organization Overview

First Clinical Trial
2006
NCT00503386
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

TigerMed | TIGERMED AUSTRALIA PTY LIMITED | Tigermed Consulting Co., Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Iron-Deficiency (Phase 3)

Autoimmune Diseases (Phase 1)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Deficiency Diseases (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 3)

Edema (Phase 3)

Lung Neoplasms (Phase 3)

Macular Edema (Phase 3)

Nausea (Phase 2)

Psoriasis (Phase 4)

Vomiting (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 33
  • # of Trial APIs: 35